Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q4 EPS by 8c
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $232.80 -3.23%
EPS Growth %: -20.4%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -20.4%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q4 EPS of $1.17, $0.08 better than the analyst estimate of $1.09. Revenue for the quarter came in at $83.5 million versus the consensus estimate of $80.84 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals, Inc. (JAZZ) click here.
For earnings history and earnings-related data on Jazz Pharmaceuticals, Inc. (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
- KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
